Takeda Expects Limited Exposure To US-China Tariffs - Takeda Pharmaceutical Co (NYSE:TAK)

Takeda Pharmaceutical to invest $30bn in US over 5 years: CEO

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO Christophe Weber said Thursday, w

Takeda Expects Limited Exposure To US-China Tariffs - Takeda Pharmaceutical Co (NYSE:TAK)

Takeda Pharmaceutical Company Limited (NYSE:TAK) reported a fiscal year 2024 net profit of 107.9 billion yen (around $709.86 million), down 25.1% year over year. Core net profit increased 2.5% (down 3.4% at constant currency) to 775.6 billion yen. Takeda CEO Christophe Weber said, "Takeda delivered excellent results in FY2024. Our return to Core Operating Profit margin growth underscores the strength of our Growth & Launch Products portfolio and…

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

OSAKA, Japan -- Takeda ( TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management.

Takeda announces handful of pipeline cuts in effort to ‘pivot resources’

Takeda revealed a handful of pipeline cuts in its fourth-quarter earnings results on Thursday, as the company focuses its attention on six late-stage programs it says could deliver billions of dollars in sales. The cuts ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Faces Market Challenges Despite Strong Product Momentum

Takeda reported an earnings per share (EPS) of -$0.23, missing the estimated EPS of -$0.03, indicating challenges in meeting market expectations. The company’s revenue was approximately $7.34 billion, below the estimated $8.02 billion, yet it showed an increase in revenue and Core Operating Profit for fiscal year 2024. Takeda’s financial health is highlighted by a […]